Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, ...

CAN-2409 plus prodrug (valacyclovir) has been granted fast track designation by the FDA for the treatment of PDAC, stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor ...

CAN-2409 plus prodrug (valacyclovir) has been granted fast track designation by the FDA for the treatment of PDAC, stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor ...

The diagnostic test of choice would be a CT scan with IV contrast to pick up most, if not all, of the other potentially dangerous conditions on the differential diagnosis. The patient’s lipase ...

Non-Hodgkin’s Lymphoma: Rutherrin® is the Company’s lead compound currently under development for Intra Venous (“IV”) administration to treat numerous cancers; including: brain, lung, pancreatic and ...